Moraes, F.C.A.d.; de Oliveira Almeida, G.; Alves, V.F.C.; Priantti, J.N.; Gomes, G.d.C.; Carnevalli, S.V.B.; Madeira, T.; Vilbert, M.; Stecca, C.; Figueroa Magalhães, M.C.;
et al. Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. J. Pers. Med. 2024, 14, 464.
https://doi.org/10.3390/jpm14050464
AMA Style
Moraes FCAd, de Oliveira Almeida G, Alves VFC, Priantti JN, Gomes GdC, Carnevalli SVB, Madeira T, Vilbert M, Stecca C, Figueroa Magalhães MC,
et al. Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. Journal of Personalized Medicine. 2024; 14(5):464.
https://doi.org/10.3390/jpm14050464
Chicago/Turabian Style
Moraes, Francisco Cezar Aquino de, Gustavo de Oliveira Almeida, VinÃcius Freire Costa Alves, Jonathan N. Priantti, Giovanna da Conceição Gomes, Sarah Vitória Bristot Carnevalli, Thiago Madeira, Maysa Vilbert, Carlos Stecca, Maria Cristina Figueroa Magalhães,
and et al. 2024. "Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials" Journal of Personalized Medicine 14, no. 5: 464.
https://doi.org/10.3390/jpm14050464
APA Style
Moraes, F. C. A. d., de Oliveira Almeida, G., Alves, V. F. C., Priantti, J. N., Gomes, G. d. C., Carnevalli, S. V. B., Madeira, T., Vilbert, M., Stecca, C., Figueroa Magalhães, M. C., Fernandes, M. R., & dos Santos, N. P. C.
(2024). Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials. Journal of Personalized Medicine, 14(5), 464.
https://doi.org/10.3390/jpm14050464
